# Effective Date of Requirement for Premarket Approval for Blood Lancets
> **Food and Drug Administration** · Final order. · Published 2021-11-22 · Effective 2021-11-22 · 86 FR 66177
## Document
- **Document number:** 2021-25381
- **Category:** fda-device
- **Sub-agency:** Food and Drug Administration
- **Federal Register citation:** 86 FR 66177
- **CFR reference:** 21 CFR 878
- **Publication date:** 2021-11-22
- **Effective date:** 2021-11-22
- **HHS docket:** Docket No. FDA-2016-M-0035
## Abstract

The Food and Drug Administration (FDA, Agency, or we) is issuing a final order to require the filing of a premarket approval application (PMA) or notice of completion of a product development protocol (PDP) following the reclassification of multiple use blood lancets for multiple patient use from class I to class III.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2021/11/22/2021-25381/effective-date-of-requirement-for-premarket-approval-for-blood-lancets)
---
*AI Analytics · CC0 1.0*